SESSION 1 - NEW INSIGHTS IN THE BIOLOGY AND DIAGNOSIS OF ITP

Welcome and introduction
F. Rodeghiero
Introduction: unmet biological needs
J.W. Semple
Role of B-cell and autoantibodies in the pathophysiology of ITP
M. Mahevas - NOT AUTHORIZED
Role of T-cell in the pathophysiology of IT
A. Malik - NOT AUTHORIZED
Platelet-antibodies: multilevel regulators in ITP
R. Kapur - NOT AUTHORIZED
SESSION 2 - NEW DEVELOPMENTS IN DEFINITIONS, GUIDELINES; NATIONAL ITP REGISTRIES

Introduction: why do we need new definitions and guidelines?
C.E. Neunert
Where do we stand with the new EHA guidelines
W. Ghanima - NOT AUTHORIZED
What can we learn from registries in ITP?
G. Moulis
Updating definitions and outcome criteria in ITP: an ERCI IWG initiative
F. Rodeghiero
SESSION 3 - ITP TREATMENT: ADDRESSING UNMET CLINICAL NEEDS AND FUTURE THERAPIES

Introduction: unmet clinical needs
J.B. Bussel - NOT AUTHORIZED
What’s new with TPO-RA
M.L. Lozano
Real world data with fostamatinib in ITP patients
M.E. Mingot Castellano
Combination therapies for refractory disease
T.J. González-López
The role of BTK in ITP
N. Cooper - NOT AUTHORIZED
New treatments
H. Al-Samkari
SESSION 4 - ITP IN SPECIFIC SITUATIONS (SECONDARY ITP, THROMBOSIS IN PATIENTS WITH ITP, ADOLESCENCE)

Introduction
V. De Stefano
ITP secondary to immunotherapeutic agents
E. Lucchini
Evans syndrome
B. Fattizzo
ITP associated with SLE/APS
B. Godeau - NOT AUTHORIZED
ITP in adolescents and young adults
A. Schifferli - NOT AUTHORIZED
Impact of fatigue and reduced HRQoL
H. Frederiksen
SESSION 5 - ABSTRACTS and ONGOING TRIALS SESSION

OC1 - A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH CHRONIC IMMUNE THROMBOCYTOPENIA (AVA-PED-301)
R.F. Grace
OC2 - Successful treatment of multi refractory primary ITP with CD19 chimeric antigen receptor T-cells
K. Trautmann-Grill - NOT AUTHORIZED
OC3 - WHOLE EXOME SEQUENCING OF PATIENTS WITH ADULT ONSET EVANS SYNDROME: A COHORT OF 120 PATIENTS
E. Crickx
OC4 - THE ROLE OF GENETIC SEQUENCING IN THE DIAGNOSTIC WORK UP FOR CHRONIC IMMUNE THROMBOCYTOPENIA
N. Joshi - NOT AUTHORIZED
OC5 - COGNITIVE IMPAIRMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
C. Vladescu - NOT AUTHORIZED
OC6 - USE OF SECOND-LINE TREATMENTS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA IN EUROPE. A PARALLEL STUDY IN SIX PROSPECTIVE MULTICENTER NATIONAL REGISTRIES
G. Moulis
OC7 - PRECLINICAL CHARACTERIZATION OF PIRTOBRUTINIB, A NON-COVALENT (REVERSIBLE) BRUTON TYROSINE KINASE INHIBITOR, IN ITP
T..J. Gonzalez-Lopez
Posters

P01 - PHASE 4 ADOPT STUDY: INTERIM ANALYSIS OF EFFICACY AND SAFETY RESULTS OF AVATROMBOPAG TREATMENT IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA
M.T. Álvarez Román
P02 - A EUROPEAN RETROSPECTIVE STUDY TO DESCRIBE REAL-WORLD OUTCOMES IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA TREATED WITH AVATROMBOPAG: INTERIM RESULTS
F. Zaja
P03 - UPDATE ON ITP PATIENTS TREATED WITH AVATROMBOPAG: A REAL-LIFE MONOCENTRIC EXPERIENCE
S. D Angelo
P04 - FOSTAMATINIB IN POLYMORBID CARDIOVASCULAR PATIENTS: WHEN AND WHOM? A MONOCENTRIC REAL LIFE EXPERIENCE
C. Giubbilei
P05 - THE OCCURANCE OF THROMBOSIS IN ITP PATIENTS ON TPORAS IN ROYAL UNITED HOSPITAL, BATH, UK
B. Bentil-Tumil
P06 - ASSESSING REFERRAL AND CORTICOSTEROID INITIATION PATTERNS IN ISOLATED THROMBOCYTOPENIA: A 2023 PATIENT COHORT STUDY AT THE ROYAL UNITED HOSPITAL, BATH
W. Hwessa
P07 - CONTRIBUTION OF THE INTESTINAL MICROBIOTA AND THE OXIDATION-REDUCTION SYSTEM IN STABILIZING PLATELET (PLT) COUNT IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
G. Tolomelli
P08 - IMMUNE THROMBOCYTOPENIA AND IMMUNOGLOBULIN G4-RELATED DISEASE: IS THERE A CORRELATION?
D. Lame
P09 - IMPACT OF THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) TREATMENT AND ADHERENCE IN PATIENTS (PTS) WITH PRIMARY CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): RESULTS OF AN INTERNATIONAL CROSS-SECTIONAL SURVEY
J.J. Zwaginga
Privacy Policy | Cookie Policy